Bausch Health And Clearside Biomedical Announce U.S. FDA Filing Acceptance For XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension)PRNewsWire • 06/02/21
Bausch + Lomb and Prevent Blindness Launch Educational Campaign During Cataract Awareness MonthPRNewsWire • 06/01/21
Bausch Health To Reduce Debt By $100 Million Using Cash Generated From OperationsPRNewsWire • 05/27/21
Bausch Health Companies Inc. (BHC) Management Presents at Barclays High Yield Bond Conference (Transcript)Seeking Alpha • 05/25/21
Bausch Health Commences Cash Tender Offer For Any And All Of Its 7.00% Senior Secured Notes Due 2024PRNewsWire • 05/24/21
Bausch Health Announces Launch Of Private Offering Of Senior Secured Notes And Conditional Redemption Of Existing Senior Secured NotesPRNewsWire • 05/24/21
Bausch Health Companies Inc. (BHC) Presents at Goldman Sachs 6th Annual Credit and Leveraged Finance Conference (Transcript)Seeking Alpha • 05/17/21
Bausch Health Companies' (BHC) CEO Joe Papa on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/04/21
Bausch Health Issues Form 8-K for 2021 Annual Meeting of Shareholders PresentationPRNewsWire • 04/27/21
Bausch Health Announces VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, is Now Approved In BrazilPRNewsWire • 04/16/21